Clinical Trial Update: NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations. [Phase 2]

View source ↗

Summary

The Phase 2 neoadjuvant gefitinib trial for unresectable stage III non-small cell lung cancer with EGFR mutations has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Cancer | Phase 2 | Status: WITHDRAWN